SFI
ASND icon

Susquehanna Fundamental Investments’s Ascendis Pharma A/S ASND Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-11,807
Closed -$1.97M – 1529
2020
Q4 		$1.97M Buy
11,807
+4,707
+66% +$778K 0.04% 626
2020
Q3 		$1.1M Buy
+7,100
New +$1.02M 0.03% 609

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Susquehanna Fundamental Investments's ASND Position: Q1 2021 in Review

Susquehanna Fundamental Investments sold out of Ascendis Pharma A/S (ASND) in Q1 2021, closing a stake of 11,807 shares — an estimated $1.97M sold.

Susquehanna Fundamental Investments first reported a position in ASND in Q3 2020 and held it in 2 quarters. The position peaked at $1.97M in Q4 2020. 177 funds tracked by Wall St. Rank hold ASND as of Q1 2021.

  • Susquehanna Fundamental Investments reported no remaining Ascendis Pharma A/S position as of Q1 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 11,807 Ascendis Pharma A/S shares in Q1 2021, an estimated $1.97M.
  • Susquehanna Fundamental Investments first reported a position in Ascendis Pharma A/S in Q3 2020 and held it in 2 quarters.
  • Susquehanna Fundamental Investments's Ascendis Pharma A/S position peaked at $1.97M in Q4 2020.
  • 177 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2021, filed 17 May 2021.